JP2016530290A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530290A5 JP2016530290A5 JP2016539635A JP2016539635A JP2016530290A5 JP 2016530290 A5 JP2016530290 A5 JP 2016530290A5 JP 2016539635 A JP2016539635 A JP 2016539635A JP 2016539635 A JP2016539635 A JP 2016539635A JP 2016530290 A5 JP2016530290 A5 JP 2016530290A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- composition
- cancer
- seq
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 100
- 239000000203 mixture Substances 0.000 claims description 55
- 150000001413 amino acids Chemical class 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 11
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 claims description 7
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 claims description 7
- 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 claims description 7
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 claims description 7
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 claims description 7
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 claims description 6
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 claims description 6
- -1 hTERT Proteins 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 claims description 5
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 claims description 5
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 5
- 102100034256 Mucin-1 Human genes 0.000 claims description 5
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 4
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 3
- 108010002687 Survivin Proteins 0.000 claims description 3
- 102000040856 WT1 Human genes 0.000 claims description 3
- 108700020467 WT1 Proteins 0.000 claims description 3
- 101150084041 WT1 gene Proteins 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 101150029707 ERBB2 gene Proteins 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000005867 T cell response Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1315946.2A GB201315946D0 (en) | 2013-09-06 | 2013-09-06 | Oncology vaccine |
| GB1315946.2 | 2013-09-06 | ||
| PCT/GB2014/052675 WO2015033140A1 (en) | 2013-09-06 | 2014-09-04 | Oncology vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016530290A JP2016530290A (ja) | 2016-09-29 |
| JP2016530290A5 true JP2016530290A5 (OSRAM) | 2017-10-12 |
Family
ID=49486881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539635A Pending JP2016530290A (ja) | 2013-09-06 | 2014-09-04 | 腫瘍学ワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160199469A1 (OSRAM) |
| EP (1) | EP3041493A1 (OSRAM) |
| JP (1) | JP2016530290A (OSRAM) |
| KR (1) | KR20160131998A (OSRAM) |
| AU (1) | AU2014316791A1 (OSRAM) |
| CA (1) | CA2922467A1 (OSRAM) |
| GB (1) | GB201315946D0 (OSRAM) |
| MX (1) | MX2016002937A (OSRAM) |
| WO (1) | WO2015033140A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7090335B2 (ja) | 2015-09-25 | 2022-06-24 | イムサイス エスエー | 治療剤に対する免疫応答を除去するための改善された方法及び化合物 |
| GB201520539D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| WO2017096247A1 (en) | 2015-12-04 | 2017-06-08 | Mayo Foundation For Medical Education And Research | Methods and vaccines for inducing immune responses to multiple different mhc molecules |
| ES2965957T3 (es) | 2016-06-02 | 2024-04-17 | Ultimovacs Asa | Una vacuna junto con un inhibidor del punto de control inmunitario para usar en el tratamiento del cáncer |
| CR20210128A (es) * | 2017-01-27 | 2021-04-26 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cancer (divisional exp. 2019-388) |
| IL268920B2 (en) | 2017-03-03 | 2025-05-01 | Treos Bio Zrt | Peptide vaccines |
| AU2018250226B2 (en) | 2017-04-04 | 2025-04-24 | Barinthus Biotherapeutics North America, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| AU2019249232A1 (en) * | 2018-04-04 | 2020-10-22 | Altimmune Inc | T-cell inducing vaccine composition combinations and uses thereof |
| FI3773689T3 (fi) * | 2018-04-11 | 2023-01-31 | Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon | |
| CN112912387A (zh) * | 2018-08-22 | 2021-06-04 | 弗雷德哈钦森癌症研究中心 | 靶向kras或her2抗原的免疫疗法 |
| GB201814362D0 (en) * | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Composition and process for preparing vaccine |
| US11666644B2 (en) | 2018-09-04 | 2023-06-06 | Treos Bio Limited | Peptide vaccines |
| GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
| CA3182959A1 (en) * | 2020-05-12 | 2021-11-18 | Sumitomo Pharma Co., Ltd. | Pharmaceutical composition for treating cancer |
| CN118909138A (zh) * | 2024-04-29 | 2024-11-08 | 北京臻知医学科技有限责任公司 | 一种肿瘤疫苗及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999053061A2 (en) * | 1998-04-15 | 1999-10-21 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
| US6534482B1 (en) * | 1998-05-13 | 2003-03-18 | Epimmune, Inc. | Expression vectors for stimulating an immune response and methods of using the same |
| US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| US7063854B1 (en) * | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| US20030224036A1 (en) * | 1999-12-13 | 2003-12-04 | Fikes John D | Hla class I a2 tumor associated antigen peptides and vaccine compositions |
| WO2001055393A2 (en) * | 2000-01-28 | 2001-08-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |
| AUPQ776100A0 (en) * | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
| WO2005033278A2 (en) * | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
| GB0408164D0 (en) * | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| EP1748067A1 (en) * | 2005-07-29 | 2007-01-31 | Institut Pasteur | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes |
| GB0609121D0 (en) * | 2006-05-09 | 2006-06-21 | Univ Birmingham | Peptide Therapy |
| CN102088994B (zh) * | 2008-04-17 | 2014-06-25 | 海莱乌医院 | 基于吲哚胺2，3-双加氧酶的免疫疗法 |
| TW201008574A (en) * | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| GB201019331D0 (en) * | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
| US8987423B2 (en) * | 2010-07-22 | 2015-03-24 | Glaxosmithkline Biologicals, S.A. | MAGE antigen binding proteins |
| GB201022147D0 (en) * | 2010-12-31 | 2011-02-16 | Immune Targeting Systems Its Ltd | Formulation |
| US20120328660A1 (en) * | 2011-06-03 | 2012-12-27 | Tsuji Takemasa | Immunogenic compositions useful in provoking an integrated response to tumor antigens |
-
2013
- 2013-09-06 GB GBGB1315946.2A patent/GB201315946D0/en not_active Ceased
-
2014
- 2014-09-04 US US14/916,813 patent/US20160199469A1/en not_active Abandoned
- 2014-09-04 WO PCT/GB2014/052675 patent/WO2015033140A1/en not_active Ceased
- 2014-09-04 KR KR1020167009027A patent/KR20160131998A/ko not_active Ceased
- 2014-09-04 AU AU2014316791A patent/AU2014316791A1/en not_active Abandoned
- 2014-09-04 MX MX2016002937A patent/MX2016002937A/es unknown
- 2014-09-04 CA CA2922467A patent/CA2922467A1/en not_active Abandoned
- 2014-09-04 EP EP14762073.6A patent/EP3041493A1/en not_active Withdrawn
- 2014-09-04 JP JP2016539635A patent/JP2016530290A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530290A5 (OSRAM) | ||
| JP7253210B2 (ja) | Ｗｔ１抗原ペプチドおよび免疫調節剤の併用 | |
| Milani et al. | Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives | |
| JP2018509936A5 (OSRAM) | ||
| Milani et al. | Recent advances in the development of breast cancer vaccines | |
| RU2019106663A (ru) | Комбинированная терапия рака | |
| ES2460899T3 (es) | Inmunoterapia basada en células cancerosas alógenas | |
| Freiser et al. | The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities | |
| KR20180118702A (ko) | 방광암 및 기타 암들에 대한 면역요법에서의 사용을 위한 펩티드, 펩티드의 조합 및 세포 기반 약제들 | |
| Matijevic Glavan et al. | The exploitation of Toll-like receptor 3 signaling in cancer therapy | |
| WO2015193359A3 (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
| CN108392633A (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| Safavi et al. | Efficacy of co-immunization with the DNA and peptide vaccines containing SYCP1 and ACRBP epitopes in a murine triple-negative breast cancer model | |
| Tagliamonte et al. | Potentiating cancer vaccine efficacy in liver cancer | |
| JP2019517544A5 (OSRAM) | ||
| Kameshima et al. | Immunogenic enhancement and clinical effect by type‐I interferon of anti‐apoptotic protein, survivin‐derived peptide vaccine, in advanced colorectal cancer patients | |
| IL240695B1 (en) | Nme inhibitors and methods of using nme inhibitors | |
| Nakajima et al. | Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration | |
| JP2018528960A5 (OSRAM) | ||
| Miyako et al. | Antitumor effect of new HER2 peptide vaccination based on B cell epitope | |
| JP4780540B2 (ja) | サバイビン由来癌抗原ペプチド | |
| Báez et al. | HER1-based vaccine: simultaneous activation of humoral and cellular immune response | |
| CN105407916A (zh) | 二价疫苗组合物以及其用于治疗肿瘤的用途 | |
| JP2017500305A5 (OSRAM) | ||
| Lollini et al. | Preclinical HER-2 vaccines: from rodent to human HER-2 |